Rodgers Brothers’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.7M | Buy |
77,551
+11
| +0% | +$641 | 0.54% | 53 |
|
|
2025
Q4 | $4.18M | Sell |
77,540
-1,187
| -2% | -$57.1K | 0.5% | 56 |
|
|
2025
Q3 | $3.55M | Sell |
78,727
-337
| -0.4% | -$15.7K | 0.44% | 64 |
|
|
2025
Q2 | $3.66M | Buy |
79,064
+12
| +0% | +$589 | 0.46% | 64 |
|
|
2025
Q1 | $4.82M | Sell |
79,052
-290
| -0.4% | -$16.9K | 0.64% | 44 |
|
|
2024
Q4 | $4.49M | Buy |
79,342
+10
| +0% | +$559 | 0.59% | 49 |
|
|
2024
Q3 | $4.1M | Buy |
79,332
+24,961
| +46% | +$1.17M | 0.52% | 60 |
|
|
2024
Q2 | $2.26M | Buy |
54,371
+11,903
| +28% | +$533K | 0.31% | 93 |
|
|
2024
Q1 | $2.3M | Buy |
42,468
+1,135
| +3% | +$57.8K | 0.31% | 89 |
|
|
2023
Q4 | $2.12M | Sell |
41,333
-16,290
| -28% | -$855K | 0.33% | 83 |
|
|
2023
Q3 | $3.34M | Buy |
57,623
+4,033
| +8% | +$247K | 0.57% | 56 |
|
|
2023
Q2 | $3.43M | Buy |
53,590
+3,565
| +7% | +$239K | 0.6% | 55 |
|
|
2023
Q1 | $3.47M | Buy |
50,025
+23,050
| +85% | +$1.63M | 0.67% | 49 |
|
|
2022
Q4 | $1.94M | Sell |
26,975
-430
| -2% | -$32.4K | 0.39% | 71 |
|
|
2022
Q3 | $1.95M | Sell |
27,405
-36,036
| -57% | -$2.61M | 0.42% | 72 |
|
|
2022
Q2 | $4.88M | Sell |
63,441
-277
| -0.4% | -$21.1K | 0.97% | 31 |
|
|
2022
Q1 | $4.65M | Hold |
63,718
| – | – | 0.84% | 38 |
|
|
2021
Q4 | $3.97M | Buy |
63,718
+17,500
| +38% | +$1.03M | 0.71% | 41 |
|
|
2021
Q3 | $2.73M | Buy |
46,218
+200
| +0.4% | +$13.2K | 0.55% | 54 |
|
|
2021
Q2 | $3.08M | Buy |
46,018
+10,350
| +29% | +$675K | 0.59% | 53 |
|
|
2021
Q1 | $2.25M | Buy |
35,668
+1,700
| +5% | +$106K | 0.47% | 61 |
|
|
2020
Q4 | $2.11M | Sell |
33,968
-100
| -0.3% | -$6.15K | 0.48% | 61 |
|
|
2020
Q3 | $2.05M | Buy |
34,068
+13,586
| +66% | +$818K | 0.53% | 49 |
|
|
2020
Q2 | $1.2M | Buy |
20,482
+477
| +2% | +$28.5K | 0.33% | 75 |
|
|
2020
Q1 | $1.11M | Buy |
20,005
+254
| +1% | +$15.5K | 0.35% | 72 |
|
|
2019
Q4 | $1.27M | Buy |
+19,751
| New | +$1.13M | 0.33% | 81 |
|
|
2019
Q3 | – | Sell |
-5,373
| Closed | -$244K | – | 189 |
|
|
2019
Q2 | $244K | Buy |
5,373
+930
| +21% | +$43.3K | 0.07% | 177 |
|
|
2019
Q1 | $212K | Buy |
4,443
+12
| +0.3% | +$598 | 0.06% | 182 |
|
|
2018
Q4 | $230K | Sell |
4,431
-488
| -10% | -$26.2K | 0.07% | 175 |
|
|
2018
Q3 | $305K | Buy |
4,919
+10
| +0.2% | +$593 | 0.09% | 162 |
|
|
2018
Q2 | $272K | Buy |
+4,909
| New | +$265K | 0.08% | 165 |
|
|
2017
Q4 | – | Sell |
-6,785
| Closed | -$432K | – | 176 |
|
|
2017
Q3 | $432K | Buy |
+6,785
| New | +$396K | 0.15% | 118 |
|
Other funds holding BMY
VCM
VPM
Rodgers Brothers's BMY Position: Q1 2026 in Review
Rodgers Brothers increased its Bristol-Myers Squibb (BMY) stake by 0.01% in Q1 2026, buying an estimated $641 and bringing the position to 77,551 shares worth $4.7M. The position accounts for 0.54% of the portfolio, ranked #53.
Rodgers Brothers first reported a position in BMY in Q3 2017 and has held it in 32 quarters since. The position peaked at $4.88M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Rodgers Brothers held 77,551 shares of Bristol-Myers Squibb worth $4.7M as of Q1 2026.
- Rodgers Brothers bought 11 Bristol-Myers Squibb shares in Q1 2026, an estimated $641.
- Bristol-Myers Squibb made up 0.54% of Rodgers Brothers's portfolio in Q1 2026, its #53 holding.
- Rodgers Brothers first reported a position in Bristol-Myers Squibb in Q3 2017 and has held it in 32 quarters since.
- Rodgers Brothers's Bristol-Myers Squibb position peaked at $4.88M in Q2 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Rodgers Brothers's 13F filing for Q1 2026, filed 14 May 2026.